Publications

Search our bibliography using the filters on the right-hand side.

Displaying 51 through 79 of 79 publications.

Elewski B, Williams N, Mollon P, Sherif B, Fox T, Papavassilis C, Puig L. Psoriasis skin clearance is associated with patient-reported impact. Poster presented at the 24th European Academy of Dermatology and Venereology Congress; October 2015. Copenhagen, Denmark.

Strober B, Blauvelt A, Zhao Y, Milutinovic M, Mollon P, You R, Sherif B, Williams N, Fox T, Augustin M, Lebwohl M. Secukinumab treatment provides more effective relief from patient-reported psoriasis-related pain, itching, and scaling than ustekinumab. Poster presented at the 24th European Academy of Dermatology and Venereology Congress; October 2015. Copenhagen, Denmark.

Blauvelt A, Korman N, Mollon P, Zhao Y, Milutinovic M, You R, Sherif B, Williams N, Fox T, Augustin M. Secukinumab treatment provides faster and more effective relief from patient-reported quality of life impact than ustekinumab in subjects with moderate to severe plaque psoriasis. Poster presented at the 24th European Academy of Dermatology and Venereology Congress; October 2015. Copenhagen, Denmark.

Gossec L, Kvien TK, Conaghan PG, Ostergaard M, Canete JD, Gaillez C, Mpofu S, Sherif B, Jugl S. Relationship between improvements in fatigue and signs & symptoms of active psoriatic: arthritis a sub-analysis of a phase 3 study with secukinumab. Poster presented at the 2015 ACR/ARHP Annual Meeting; November 10, 2015. San Francisco, CA. [abstract] Arthritis Rheumatol. 2015 Sep 29; 67(Suppl 10).

Odom DM, McLeod LD, Sherif BN, Nelson LM. Methods to assess the association of patient-reported outcomes and clinical endpoints. Presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA.

Foley P, Sherif B, Mallya UG, Fox T, Gottlieb AB. Secukinumab treatment sustains patient-reported outcome benefits through 1 year. Poster presented at the 48th Australasian College of Dermatologists Annual Scientific Meeting; May 2015. Adelaide, Australia. [abstract] Australas J Dermatol. 2015 May; 56(Suppl 2):56.

Sherrill B, Fernandez MM, Wang J, Xin Y, Kwong WJ, Sherif BN, Hogue SL. Network meta-analysis of relative efficacy and safety of edoxaban versus other novel oral anticoagulants (NOACs) among atrial fibrillation patients with CHADS2 score greater than or equal to 2. Poster presented at the American College of Cardiology; March 16, 2015. San Diego, CA.

Sherif BN, Mallya UG, Fox T, Gottlieb AB. Secukinumab treatment sustains patient-reported outcome benefits through 1 year. Poster presented at the 23rd European Academy of Dermatology and Venereology Congress; October 8, 2014.

Odom DM, Chirila C, Sherrill EH, Wang J, Sherif BN. Practical issues when conducting network meta-analyses with a limited number of studies. Poster presented at the 2014 ISPOR 19th Annual International Meeting; June 3, 2014.

Odom DM, Mladsi DM, Saag KG, Sherif BN, Miles L, Ronquest N, Wang J. Relationship between diclofenac dose and risk of gastrointestinal and cardiovascular events: meta-regression based on two systematic literature reviews. Clin Ther. 2014 Jun;36(6):906-17. doi: 10.1016/j.clinthera.2014.04.012.

Messiah SE, Lopez-Mitnik G, Winegar D, Sherif BN, Arheart KL, Reichard KW, Michalsky MP, Lipshultz SE, Miller TL, Livingstone AS, de la Cruz-Muñoz N. Effect of ethnicity on weight loss among adolescents 1 year after bariatric surgery. World J Diabetes. 2013 Oct 15;4(5):202-9. doi: 10.4239/wjd.v4.i5.202

Messiah SE, Lopez-Mitnik G, Winegar D, Sherif BN, Arheart KL, Reichard KW, Michalsky MP, Lipshultz SE, Miller TL, Livingstone AS, de la Cruz-Munoz N. Changes in weight and co-morbidities among adolescents undergoing bariatric surgery: 1-year results from the Bariatric Outcomes Longitudinal Database. Surg Obes Relat Dis. 2013 Aug;9(4):503-13.

Morton J, Sherif BN, Winegar D, Nguyen N, Ponce J, Blackstone R. National comparisons of bariatric surgery safety and efficacy: findings from the BOLD database 2007-2010. Poster presented at the 29th Annual Meeting of the American Society for Metabolic and Bariatric Surgery; June 17, 2012.

Chirila C, Odom D, Devercelli G, Khan S, Sherif BN, Kaye JA, Molnar I, Sherrill B. Meta-analysis of the association between progression-free survival and overall survival in metastatic colorectal cancer. Int J Colorectal Dis. 2012 May 1;27(5):623-34.

Inabnet WB3rd, Winegar DA, Sherif BN, Sarr MG. Early outcomes of bariatric surgery in patients with metabolic syndrome: an analysis of the bariatric outcomes longitudinal database. J Am Coll Surg. 2012 Apr;214(4):550-6.

Sherrill B, Sherif B, Amonkar MM, Maltzman J, O'Rourke L, Johnston S. Quality-adjusted survival analysis of first-line treatment of hormone-receptor-positive HER2+ metastatic breast cancer with letrozole alone or in combination with lapatinib. Curr Med Res Opin. 2011 Dec 1;27(12):2245-52.

Morton JM, DeMaria E, Winegar D, Sherif BN, Hutcher N, Blackstone R. Is ambulatory laparoscopic roux en y gastric bypass from the bariatric outcomes longitudinal database (BOLD) associated with higher adverse events? Presented at the 28th Annual Meeting of the American Society for Metabolic and Bariatric Surgery; June 12, 2011.

Winegar DA, DeMaria EJ, Sherif BN, Apovian CM. Indications for bariatric surgery in the bmi<35 kg/m2 population treated at ASMBS bariatric surgery centers of excellence (BSCOE'S) as reported in the bariatric outcomes longitudinal database (BOLD). Poster presented at the 2nd World Congress on Interventional Therapies for Type 2 Diabetes; March 28, 2011.

Winegar DA, Sherif BN, Pate V, DeMaria EJ. Venous thromboembolism after bariatric surgery performed by Bariatric Surgery Center of Excellence participants: analysis of the bariatric outcomes longitudinal database. Surg Obes Relat Dis. 2011 Mar;7(2):181-8.

Chirila C, Odom D, Devercelli G, Khan S, Sherif B, Kaye J, Molnar I, Sherrill B. Meta-analysis of the validity of progression-free survival as a surrogate endpoint for overall survival in metastatic colorectal cancer trials. Poster presented at the 35th European Society for Medical Oncology Congress; October 12, 2010. [abstract] Ann Oncol. 2010 Oct; 21(suppl 8):623P.

Sherrill B, Amonkar MM, Sherif B, Maltzman J, O'Rourke L, Johnston S. Quality of life in hormone receptor–positive HER-2+ metastatic breast cancer patients during treatment with letrozole alone or in combination with lapatinib. Oncologist. 2010 Sep 1;15(9):944-53.

Sherrill EH, Amonkar MM, Sherif BN, Maltzman J, O'Rourke L, Johnston S. Quality of life in hormone receptor-positive HER-2+ metastatic breast cancer patients during treatment with letrozole alone or in combination with lapatinib. Oncologist. 2010;15(9):944-53.

Sherrill B, Amonkar M, Sherif B, Maltzman J, O'Rourke L, Johnston S. An exploration of the association of qol scores with tumor progression status in first-line hr+, her2+ mbc patients treated with lapatinib plus letrozole or letrozole alone. Poster presented at the 32nd San Antoniio Breast Cancer Symposium Annual Meeting; December 14, 2009.

Sherrill B, Amonkar MM, Sherif BN, Maltzman J, O'Rourke L, Johnston S. An exploration of the association of Quality-of-Life (QOL) scores with tumor progression status in first line hormone receptor positive, HER2+ Metastatic Breast Cancer (MBC) patients treated with lapatinib plus letrozole or letrozole alone. Poster presented at the Thirty-Second Annual CTRC‐AACR San Antonio Breast Cancer Symposium; December 2009. San Antonio, TX. [abstract] Cancer Res. 2009 Dec; 69(24 (Suppl)):5106. doi: 10.1158/0008-5472.SABCS-09-5106

Oglesby A, Sherif B, Odom D, Leahy M, Qian Y. Time and costs associated with preparing and administering zoledronic acid in patients with breast or prostate cancer and metastatic bone disease. Community Oncol. 2009 Nov 1;6(11):494-502.

Sherrill B, Sherif BN, Amonkar M, Wu Y, Maltzman J, O'Rourke L, Johnston S. Quality of life and quality-adjusted survival (Q-TWIST) in patients receiving lapatinib plus letrozole as first-line therapy in hormone receptor positive, her2+ metastatic breast cancer. Poster presented at the Cancer Symposium of the American Society of Clinical Oncology; October 10, 2009.

Sherrill B, Amonkar M, Sherif BN, Maltzman J, O'Rourke L, Johnston S. A q-twist analysis of lapatinib plus letrozole compared with letrozole alone as first-line therapy in hormone receptor positive (HR+) metastatic breast cancer (MBC). Poster presented at the Joint 15th Congress of the European Cancer Organization and 34th Congress of the European Society for Medical Oncology; September 25, 2009.

Sherif BN, Sherrill B, Amonkar M, Wu Y, Maltzman J, O'Rourke L, Johnston S. Lapatinib plus letrozole compared with letrozole alone as first-line therapy in hormone receptor positive her2+ metastatic breast cancer: a quality of life analysis. Poster presented at the 2009 ASCO Annual Meeting; June 2, 2009.

Sherrill EH, Sherif BN, Amonkar MM, Wu Y, Maltzman J, O'Rourke L, Johnston S. Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib plus letrozole as first-line therapy in hormone receptor positive, HER2+ metastatic breast cancer (MBC). Poster presented at the ASCO Breast Cancer Symposium; 2009.